{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:58:42Z","timestamp":1784667522489,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T00:00:00Z","timestamp":1417737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-014-2264-0","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T03:00:34Z","timestamp":1417662034000},"page":"651-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry"],"prefix":"10.1007","volume":"94","author":[{"given":"M. W. M.","family":"van der Poel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"2264_CR1","unstructured":"Surveillance, Epidemiology, and End Results Program. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"2264_CR2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91\u201397","journal-title":"N Engl J Med"},{"key":"2264_CR3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"},{"key":"2264_CR4","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","volume":"23","author":"JP Fermand","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65\u00a0years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol Off J Am Soc Clin Oncol 23:9227\u20139233","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2264_CR5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.bmt.1705580","volume":"39","author":"MH Qazilbash","year":"2007","unstructured":"Qazilbash MH, Saliba RM, Hosing C et al (2007) Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39:279\u2013283","journal-title":"Bone Marrow Transplant"},{"key":"2264_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2169\/internalmedicine.52.8390","volume":"52","author":"T Muta","year":"2013","unstructured":"Muta T, Miyamoto T, Fujisaki T et al (2013) Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Intern Med 52:63\u201370","journal-title":"Intern Med"},{"key":"2264_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J et al (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93:51\u201354","journal-title":"Blood"},{"key":"2264_CR8","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"A Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104:3052\u20133057","journal-title":"Blood"},{"key":"2264_CR9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E et al (2001) Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70\u00a0years. Br J Haematol 114:600\u2013607","journal-title":"Br J Haematol"},{"key":"2264_CR10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet 370:1209\u20131218","journal-title":"Lancet"},{"key":"2264_CR11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825\u2013831","journal-title":"Lancet"},{"key":"2264_CR12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","volume":"118","author":"PM Fayers","year":"2011","unstructured":"Fayers PM, Palumbo A, Hulin C et al (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239\u20131247","journal-title":"Blood"},{"key":"2264_CR13","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","volume":"28","author":"P Wijermans","year":"2010","unstructured":"Wijermans P, Schaafsma M, Termorshuizen F et al (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol Off J Am Soc Clin Oncol 28:3160\u20133166","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2264_CR14","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin C, Facon T, Rodon P et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75\u00a0years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J Clin Oncol Off J Am Soc Clin Oncol 27:3664\u20133670","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2264_CR15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"2264_CR16","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R et al (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol Off J Am Soc Clin Oncol 28:2259\u20132266","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2264_CR17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759\u20131769","journal-title":"N Engl J Med"},{"key":"2264_CR18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH et al (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10\u00a0yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311\u2013319","journal-title":"Eur J Haematol"},{"key":"2264_CR19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","volume":"72","author":"N Gulbrandsen","year":"2004","unstructured":"Gulbrandsen N, Hjermstad MJ, Wisloff F, Nordic Myeloma Study G (2004) Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 72:172\u2013180","journal-title":"Eur J Haematol"},{"key":"2264_CR20","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","volume":"90","author":"SG Verelst","year":"2011","unstructured":"Verelst SG, Termorshuizen F, Uyl-de Groot CA et al (2011) Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 90:1427\u20131439","journal-title":"Ann Hematol"},{"key":"2264_CR21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","volume":"89","author":"M Delforge","year":"2012","unstructured":"Delforge M, Dhawan R, Robinson D Jr et al (2012) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 89:16\u201327","journal-title":"Eur J Haematol"},{"key":"2264_CR22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2012.074534","volume":"98","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Delforge M, Hajek R et al (2013) Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65\u00a0years or older: results of a randomized phase III trial. Haematologica 98:784\u2013788","journal-title":"Haematologica"},{"key":"2264_CR23","volume-title":"International classification of diseases for oncology","author":"A Fritz","year":"2000","unstructured":"Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organisation, Geneva","edition":"3"},{"key":"2264_CR24","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","volume":"47","author":"LV Poll-Franse van de","year":"2011","unstructured":"van de Poll-Franse LV, Horevoorts N, van Eenbergen M et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47:2188\u20132194","journal-title":"Eur J Cancer"},{"key":"2264_CR25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ejca.2010.11.004","volume":"47","author":"LV Poll-Franse van de","year":"2011","unstructured":"van de Poll-Franse LV, Mols F, Gundy CM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47:667\u2013675","journal-title":"Eur J Cancer"},{"key":"2264_CR26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"2264_CR27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisloff F et al (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670\u20131678","journal-title":"Eur J Cancer"},{"key":"2264_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/art.10993","volume":"49","author":"O Sangha","year":"2003","unstructured":"Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49:156\u2013163","journal-title":"Arthritis Rheum"},{"key":"2264_CR29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol Off J Am Soc Clin Oncol 29:89\u201396","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2264_CR30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol Off J Am Soc Clin Oncol 16:139\u2013144","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2264_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"2264_CR32","doi-asserted-by":"crossref","unstructured":"van der Poel MW, Oerlemans S, Schouten HC, et al (2013) Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry. Annals of Hematology","DOI":"10.1007\/s00277-013-1980-1"},{"key":"2264_CR33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ejca.2011.11.030","volume":"48","author":"F Mols","year":"2012","unstructured":"Mols F, Thong MS, Vissers P, Nijsten T, van de Poll-Franse LV (2012) Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer 48:2037\u20132042","journal-title":"Eur J Cancer"},{"key":"2264_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","volume":"36","author":"JA Goodwin","year":"2013","unstructured":"Goodwin JA, Coleman EA, Sullivan E et al (2013) Personal financial effects of multiple myeloma and its treatment. Cancer Nurs 36:301\u2013308","journal-title":"Cancer Nurs"},{"key":"2264_CR35","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","volume":"1","author":"M Kleber","year":"2011","unstructured":"Kleber M, Ihorst G, Terhorst M et al (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35","journal-title":"Blood Cancer J"},{"key":"2264_CR36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","volume":"13","author":"M Kleber","year":"2013","unstructured":"Kleber M, Ihorst G, Gross B et al (2013) Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 13:541\u2013551","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2264_CR37","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Palumbo A, Hajek R, et al (2013) Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >\/= 65\u00a0years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia & Lymphoma","DOI":"10.3109\/10428194.2013.847933"},{"key":"2264_CR38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1385\/MO:18:1:65","volume":"18","author":"N Gulbrandsen","year":"2001","unstructured":"Gulbrandsen N, Wisloff F, Brinch L et al (2001) Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18:65\u201377","journal-title":"Med Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2264-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2264-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2264-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T14:32:05Z","timestamp":1598538725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2264-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2264-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}